Skip to main content

Market Overview

Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows

Share:
  • Precision BioSciences Inc (NASDAQ: DTIL) has announced three-year follow-up data showing long-term stable reduction of low-density lipoprotein (LDL) cholesterol levels in nonhuman primates (NHPs) after in vivo gene editing of the PCSK9 gene with its ARCUS platform. The company published the data online in Molecular Therapy.
  • NHPs have demonstrated a continuous and sustained reduction in LDL cholesterol levels while maintaining stable gene editing without any noticeable adverse effects. After the one-time vector administration more than three years ago, NHPs treated with ARCUS have experienced stable reductions of up to 85% in PCSK9 protein levels and a 56% reduction of LDL cholesterol levels.
  • "To our knowledge, this is the longest duration gene editing data in a large animal model. The data demonstrates that a single administration of an ARCUS nuclease could represent a potential one-time, permanent treatment for familial hypercholesteremia," commented Derek Jantz, Ph.D., co-author of the paper and Chief Scientific Officer at Precision BioSciences.
  • ARCUS is a proprietary genome editing that uses sequence-specific DNA-cutting enzymes, or nucleases, designed to either insert (knock-in), remove (knock-out), or repair the DNA of living cell organisms.
  • Last year in November, the company announced a license agreement with Eli Lilly And Co (NYSE: LLY) for the ARCUS platform for Duchenne muscular dystrophy and two other undisclosed gene targets.
  • Price Action: DTIL shares are trading higher by 7.68% at $12.20 in the premarket session on the last check Friday.
 

Related Articles (LLY + DTIL)

View Comments and Join the Discussion!

Posted-In: Gene EditingBiotech News Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com